![]() |
市场调查报告书
商品编码
1351017
2023-2030年全球微生物发酵技术市场Global Microbial Fermentation Technology Market 2023-2030 |
预计在预测期(2023-2030年),全球微生物发酵技术市场将以5.9%的复合年增长率成长。推动全球微生物发酵技术市场成长的主要因素包括工业发酵的兴起,工业发酵用于生产化学品、材料、生物燃料、膳食和药品。采用发酵技术的主要目的是使用基于培养或分子的方法来改变代谢途径。发酵是製药公司生产重组产品(例如重组蛋白、疫苗和荷尔蒙)的常用方法。例如,2023 年 5 月,Ardra Inc. 生产天然食品成分,如植物性肉类替代品、健康和营养添加剂以及天然防腐剂。 Ardra 透过精密发酵技术,以更永续、更实惠的方式生产天然成分,并提供可靠的供应。
全球微生物发酵技术市场按技术、应用和最终用户细分。根据技术,市场细分为分批补料发酵、固态发酵和连续搅拌槽反应器。根据应用,市场细分为抗生素、疫苗、溶剂和中间化合物。此外,根据最终用户,市场细分为生物製药行业、食品和饲料行业、CRO和CMO以及学术研究机构。在最终用户中,由于超音波、欧姆加热、MEF、PEF和冷等离子体等新兴创新技术的发展不断增长,预计生物製药行业细分市场将占据相当大的市场份额。这些极大地改善了发酵技术的市场。
其中,抗生素细分领域预计将在全球微生物发酵技术市场中占据相当大的份额。该细分市场的成长归因于全球健康问题、製药业投资、新菌株的发现、生物技术的进步以及对抗生素日益增长的需求的影响力不断增强。为了提高产能,新设施和改进的流程为公司带来了重要的永续性改善。例如,2023年2月,赢创工业股份公司的动物营养公司产品线更加关注抗菌生长促进剂,致力于提供确保动物健康和性能、保护人类健康并满足日益增长的高需求的解决方案。全球优质动物性蛋白质。
全球微生物发酵技术市场根据地理位置进一步细分,包括北美(美国和加拿大)、欧洲(英国、义大利、西班牙、德国、法国和欧洲其他地区)、亚太地区(印度、中国、日本、韩国和亚洲其他地区)以及世界其他地区(中东和非洲以及拉丁美洲。其中,北美预计将在全球市场中占据显着份额。不断变化的格局生物製品生产的增长是该地区市场的主要驱动因素。该地区的主要市场参与者包括Ferment.Co、Perfect Day、Geltor, Inc.、The EVERY Co. 等。
在所有地区中,亚太地区预计在预测期内将以相当大的复合年增长率成长。公司越来越多地参与生物製剂研究和产品开发,以及该地区存在大量合约开发组织,都是促进区域成长的因素。由于影响生物製药外包的因素的融合,该地区对微生物发酵技术的需求将会增加。为了满足国内需求,中国将兴建一批生物加工厂。
强而有力的监管架构是塑造亚太市场的另一个关键因素。印度、中国、日本继续努力改进有关生物製药产品的推广、开发、批准和法律实践的指导方针。中国是亚太地区的主要收入贡献者。影响中国产业的关键因素之一是生物製剂製造方式的改变。由于生物製药研发支出不断增加以及 GMP 製造采用令人难以置信的创新技术,该市场不断增长。
Title: Global Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Technology (Fed-Batch Fermentation, Solid-State Fermentation, and Continuous Stirred-Tank Reactor), by Application (Antibiotics, Vaccines, Solvents, and Intermediary compounds), and by End-Users (Bio-Pharmaceutical Industries, Food and Feed Industries, CROs and CMOs, and Academic Research Institutes),Forecast Period (2023-2030).
The global microbial fermentation technology market is anticipated to grow at a CAGR of 5.9% during the forecast period (2023-2030). The major factor driving the global microbial fermentation technology market growth includes the rising industrial fermentation, which is used to generate chemicals, materials, biofuels, meals, and medicines. The main purpose in adoption of fermentation technology is to alter the metabolic pathways using cultivation-based or molecular approaches. Fermentation is a common method used by pharmaceutical companies to manufacture recombinant goods such as recombinant proteins, vaccines, and hormones. For instance, in May 2023, Ardra Inc. produces natural food ingredients such as plant-based meat substitutes, health and nutritional additives, and natural preservatives. Ardra produces natural ingredients more sustainably, more affordably, and with reliable supply via precision fermentation technology.
The global microbial fermentation technology market is segmented by technology, application, and end-users. Based on the technology, the market is sub-segmented into fed-batch fermentation, solid-state fermentation, and continuous stirred-tank reactors. Based on the application, the market is sub-segmented into antibiotics, vaccines, solvents, and intermediary compounds. Further, on the basis of end-users, the market is sub-segmented into bio-pharmaceutical industries, food and feed industries, CROs and CMOs, and academic research institutes. Among the end-users, the bio-pharmaceutical industries sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of emerging innovative technologies such as ultrasound, ohmic heating, MEF, PEF, and cold plasma, these have significantly improved the market for fermentation technologies.
Among the application, the antibiotic sub-segment is expected to hold a considerable share of the global microbial fermentation technology market. The segmental growth is attributed to the growing influence of global health concerns, pharmaceutical industry investment, the discovery of new strains, advancements in biotechnology, and the increasing need for antibiotics. To boost production capacity, the new facilities and improved processes bring important sustainability improvements for the company. For instance, in February 2023, Evonik Industries AG's Animal Nutrition Company Line, with a larger focus on antimicrobial growth promoters, strives to offer solutions that assure the health and performance of the animal, protect human health, and meet the growing demand for high-quality animal protein globally.
The global microbial fermentation technology market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe. The evolving landscape of the manufacturing of biologics is a major driving factor for the market in the region. The key market players in the region include Ferment.Co, Perfect Day, Geltor, Inc., The EVERY Co. and others.
Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Growing company involvement in biologics research and product development, together with the presence of a sizable number of contract development organizations in the area, are both factors contributing to regional growth. The region's need for microbial fermentation technology would rise as a result of the convergence of the factors affecting biopharmaceutical outsourcing. To address domestic demand, a number of bioprocessing plants are going to be built in China.
The strong regulatory framework is another key factor in shaping the Asia-Pacific market. India, China, Japan continues to make attempts to improve guidelines regarding the promotion, development, approval, and legal practice surrounding biopharmaceutical products. China is the key revenue contributor in the Asia-Pacific region. One of the key factors influencing the Chinese industry is the way biologics manufacturing is changing. The market has grown as a result of growing spending for biopharmaceutical research and development as well as the adoption of incredibly innovative technology for GMP manufacturing.
The major companies serving the global microbial fermentation technology market includes Abolis Biotechnologies, BioVectra Inc., Microbial Discovery Group, Novozymes A/S, TerraVia Holdings, Inc., and others. The market players are considerably contributing to market growth through the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Novus International Inc., a multinational animal feed and health firm, acquired Agrivida Inc. As a result of the acquisition, Novus has control of the patented INTERIUS technology that Agrivida created to embed feed ingredients inside grain.